

## Correction of Corporate Release No. 595 - Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

**Valby, Denmark, 25 August 2016** – H. Lundbeck A/S (Lundbeck) hereby corrects Company Release no. 595. The correct buyer of shares in Lundbeck is Lene Skole-Sørensen. The correction is set out in item 2.b) of the last schedule below.

1.	Details of the person discharging managerial responsibilities/person closely associated				
a)	Name	Anders Götzsche			
2.	Reason for the notific	ation			
a)	Position/status	Executive Vice President & CFO			
b)	Initial notification/ Amendment	Initial notification			
3.	Details of the issuer, or auction monitor	r, emission allowance market participant, auction platform, auctioneer			
a)	Name:	H. Lundbeck A/S			
b)	LEI-kode	Not required			
4.A.		of the transaction(s): section to be repeated for (i) each type of instrument; (ii) be of transaction; (iii) each date; and (iv) each place where transactions have been sed			
a)	Description of the financial instrument, type of instrument	Warrant			
	Identification code	DK 0010287234			
b)	Nature of the transaction	Other transaction (exercise of warrants)			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		DKK 126.66 DKK 121.79	42,478 28,318		
d)	Aggregated information — Aggregated volume — Price	70,796 124.712			
e)	Date of the transaction	2016-08-25			
f)	Place of the	H. Lundbeck A/S (the subscribed for shares will be registered on			



	transaction	NASDAQ Copenhagen XCSE)			
4.B		tion(s): section to be repeated for (i) each type of instrument; (ii) ion; (iii) each date; and (iv) each place where transactions have been			
a)	Description of the financial instrument, type of instrument	Share			
	Identification code	DK 0010287234			
b)	Nature of the transaction	Sale of share			
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		DKK 274.2186	80,361		
d)	Aggregated information - Aggregated volume - Price				
e)	Date of the transaction	2016-08-25			
f)	Place of the transaction	NASDAQ Copenhagen XCSE			

1.	Details of the person discharging managerial responsibilities/person closely associated			
a)	Name	Lene Skole-Sørensen (corrected from Anders Tormod Skole-Sørensen)		
2.	Reason for the notific	Reason for the notification		
a)	Position/status	Deputy-chairman of the Board of Directors.		
b)		Amendment. The notification in Company Release no. 595 mistakenly stated that Anders Tormod Skole-Sørensen had purchased shares in Lundbeck. The shares were purchased by Lene Skole-Sørensen. This form is amended in accordance herewith.		
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name:	H. Lundbeck A/S		
b)	LEI-code	Not required		



4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument	Share		
	Identification code	DK 0010287234		
b)	Nature of the transaction	Purchase of shares		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		272.000	917	
		272.600	915	
d)	Aggregated information - Aggregated volume	1,832		
	- Price	272.299		
e)	Date of the transaction	2016-08-25		
f)	Place of the transaction	Nasdaq Copenhagen XCSE		

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

- spouse or cohabitant
- dependent children
- legal entities in which the executive has a controlling influence.



## Lundbeck contacts

Investors:

Palle Holm Olesen Vice President, Investor Relations PALO@lundbeck.com +45 30 83 24 26 Media:

Mads Kronborg
Senior Director, Corp. Communication
MAVK@lundbeck.com
+45 36 43 40 00

## **About Lundbeck**

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this *Progress in Mind*.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.